Last reviewed 2026-04-23 · How we verify

CHEMOTHERAPY then HORMONOTHERAPY

A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth.

A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth. Used for Hormone receptor-positive breast cancer (likely primary indication based on UNICANCER focus).

At a glance

Mechanism of action

This is a combination treatment strategy rather than a single drug. Chemotherapy works through cytotoxic mechanisms to kill rapidly dividing cancer cells, while subsequent hormonotherapy (endocrine therapy) blocks hormone receptors or reduces hormone production to prevent recurrence and growth of hormone-sensitive cancer cells. The sequential approach aims to maximize efficacy by first debulking the tumor, then maintaining control through hormonal suppression.

Approved indications

• Hormone receptor-positive breast cancer (likely primary indication based on UNICANCER focus)

Common side effects

• Myelosuppression
• Nausea and vomiting
• Fatigue
• Hot flashes
• Vaginal dryness
• Thromboembolic events

Key clinical trials

• Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CHEMOTHERAPY then HORMONOTHERAPY CI brief — competitive landscape report
• CHEMOTHERAPY then HORMONOTHERAPY updates RSS · CI watch RSS
• UNICANCER portfolio CI